摘要
目的探索检测丙型肝炎病毒(HCV)高变区1(HVR1)抗体交叉反应性的意义。方法采用16种重组的HVR1抗原包被,酶联免疫吸附检测不同病程及不同干扰素治疗效果HCV感染者血清中HVR1抗体的情况,分析其高变区抗体交叉反应性。结果在慢性丙型肝炎、肝硬化和肝细胞癌这三组患者血清中HVR1抗体交叉反应阳性数目分别为10.93±4.98、12±5.57和10.64±4.83,三组间差异无统计学意义(P>0.05);对干扰素治疗效果好的患者HVR1抗体交叉反应阳性数为13.85±2.85,治疗效果差的患者为7±5.27,前者显著高于后者(P<0.05)。但两者治疗前HCV病毒载量差异无统计学意义(P>0.05)。结论 HVR1抗体的交叉反应性与HCV感染的严重程度无明显关系,但可能成为一项干扰素疗效的辅助预测指标。
Objective To evaluate the significance of cross - reactive antibodies against hypervariable region 1 （ HVR1 ） in hepatitis C virus （HCV） infected patients. Methods The cross - reactivity of HVR1 antibodies in the serum of HCV patients of different disease course and diflhrent response with interferon treatment were semiquantitatively done through counting the positive reaction with 16 representative HVRI proteins coated on the micro - plates by ELISA. Results The cross - reactivity of ItVR1 antibodies in the group of chrnnic hepatitis, cirrhosis and HCC was 10.93±4. 979, 12±5.57, 10.64±4.83 respectively. There was no significant difference in the three groups （ P 〉 0. 05 ）. The cross -reactivity of HVRI antibodies was 13.85 _ 2.85 in patients with sustained virological response （SVR） , which was significantly higher than that in the patients with no response to IFN （7±5.27 ）. There was no difference in the HCV RNA pretreatment level between the effective and ineffective groups （ P 〉 0.05 ）. Conclusion The cross - reactivity of anti - HVR1 antibody was not related to the progress of chronic HCV infection, which may be potential application in predicting the therapy outcome in chronic HCV patients.
出处
《临床肝胆病杂志》
CAS
2011年第8期818-820,共3页
Journal of Clinical Hepatology
基金
国家科技重大专项
传染病专项(2008ZX10002-013)
